News

In new guidelines, the World Health Organization (WHO) is recommending that countries significantly expand access to naloxone to help manage opioid overdoses.

The launch of the Small Business Health Options (SHOP) marketplace drew 200,000 visitors during the first week of open enrollment.

FDA is warning that a patient with multiple sclerosis (MS) who was being treated with Tecfidera (dimethyl fumarate), developed progressive multifocal leukoencephalopathy (PML), a rare and serious brain infection, and later died. As a result, information describing this case of PML is being added to the Tecfidera drug label.

Specialty pharmaceuticals will have a profound impact on the practice of pharmacy over the next 10 years, affecting all pharmacy practice settings and accelerate the importance of medication management to ensure the appropriate use of these important therapeutic agents.

The 2014 deadline for eligible hospitals and critical access hospitals (CAHs) to attest to meaningful use of electronic health records (EHRs) has been extended to December 31 by the Centers for Medicare and Medicaid Services (CMS).

Engaging patients is not simply about providing them with basic health information, but going beyond this to provide information that is truly relevant and of use to them.

There’s no hiding that hospital pharmacies have long been considered cost centers for healthcare systems. That positioning has been accentuated over the past 5 years, as the healthcare industry has seen a steady increase in high-cost, brand-name specialty medications that range from hundreds to thousands, sometimes tens of thousands, of dollars per dose. Nearly every hospital, however, has untapped opportunities to substantially improve efficiencies and improve costs. One important factor is improving how these hospitals use generic medications.

Melanoma, an aggressive disease with a rapidly rising incidence rate, presents the oncology field with some of its greatest challenges and opportunities. Long considered one of the most difficult diseases to treat with pharmacotherapy, drug development within melanoma has lagged behind that of many other cancers, culminating in decades of limited progress. Developments in molecular biology, however, have led to an increased understanding of the molecular heterogeneity of melanoma in recent years, which has resulted in new insights into the roles of oncogenes, signaling pathways, immune checkpoints, and tumor-promoting events, accelerating the rate of discovery of therapeutic targets.

Adding tumor treating fields (TTFields) therapy to temozolomide significantly increases progression-free survival (PFS) for newly diagnosed glioblastoma patients versus giving temozolomide alone, according to data presented at 2014 Society for Neuro-Oncology (SNO) Annual Meeting, in Miami.

Treating skin cancer is having a major impact on the US healthcare system. The costs associated with skin cancer increased 5 times as fast as treatments for other cancers between 2002 and 2011, according to a Centers for Disease Control study published November 9 online in the American Journal of Preventive Medicine.

Physicians debated the benefits versus the risks of aspirin for cardiovascular events in an editorial published in JAMA online November 17.

Pharmaceutical manufacturers got a better idea of the value of FDA’s Priority Review Vouchers (PRVs) recently after Gilead Sciences paid $125 million in cash for Knight Therapeutics’ Neglected Tropical Disease PRV.

Following Walmart’s entry earlier this year into primary care, Target is opening four new primary care clinics in Southern California in partnership with Kaiser Permanente.

An acute care facility replaces unproductive PCs with zero clients and no click access authentication, resulting in improved quality of care

A new Commonwealth Fund study finds that 21% of adults with health insurance spent 5% or more of their income on out-of pocket expenses and that 40% skipped medical treatment because of high deductibles.

Data from 2 phase 3 studies of lesinurad in combination with allopurinol in gout patients was presented at the American College of Rheumatology (ACR) 2014 annual meeting in Boston.

Myalept (metreleptin) is a leptin analogue with the same physiologic effects as leptin.11 Metreleptin was granted a priority review and was FDA approved on February 25, 2014, as an adjunct to diet as replacement therapy to treat the complications of leptin deficiency in patients with congenital or acquired lipodystrophy.

FDA announced that it will review results from a clinical trial showing that long-term dual antiplatelet therapy decreased the risk of heart attacks and clot formation in stents, but there was an increased overall risk of death compared to 12 months of treatment.

Investigational drug LCZ696 (Novartis), an angiotensin receptor neprilysin inhibitor (ARNI), is superior to angiotensin-converting enzyme (ACE) inhibitor alone in reducing the risks of death and of hospitalization for heart failure, according to data presented at the American Heart Association's (AHA) Scientific Sessions in Chicago.

The collective performance of U.S. hospitals on individual accountability measures is on the rise, according to a new report by The Joint Commission.

The solution to connecting streams of data in differing formats is a workflow system that can normalize data and track it to a plan member.

FDA has approved alemtuzumab (Lemtrada, Genzyme, A Sanofi Company) for the treatment of patients with relapsing forms of multiple sclerosis (MS).

The new combination hepatitis C drug ledipasvir/sofosbuvir (Harvoni, Gilead Sciences) has been found to be highly effective in treating patients with cirrhosis who have not benefited from previous therapies.

Many people who report an allergy to penicillin actually are not allergic to penicillin, according to a study presented at the American College of Allergy, Asthma and Immunology (ACAAI) Annual Scientific Meeting, in Atlanta.

Approximately half of all adults in the U.S. have one or more chronic health conditions, and 75% of health care costs are due to chronic illnesses. When psychosocial issues like depression, low income, or lack of social support are present, the impact on costs is even greater.

Opposition to the Affordable Care Act (ACA) may explain why two pairs of states had very different performance outcomes in the federally facilitated marketplace (FFM) during the first open enrollment period.

The shortage of saline solution among hospitals is ongoing and doesn’t appear to be resolving anytime soon, according to a quality executive with the American Society of Health-System Pharmacists (ASHP). In addition, safety concerns make it prohibitive for hospitals to compound their own solutions.

Healthcare executives are optimistic about telemedicine and actively pursuing telemedicine advancements despite reimbursement and regulatory challenges, according to a new survey of senior healthcare executives released today by Foley & Lardner LLP.